Interference with p53 functions in human viral infections, a target for novel antiviral strategies?

Reviews in Medical Virology

Volumn 21, Issue 5, 2011, Pages 285-300

  Lazo, Pedro A ^a   Santos, Claudio R ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; INTERFERON; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; VIRUS PROTEIN;

ADENOVIRUS; CELL STRESS; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HERPES SIMPLEX VIRUS; HUMAN CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION CONTROL; INFLUENZA VIRUS; NONHUMAN; PAPILLOMA VIRUS; PAPOVAVIRUS; PARAMYXOVIRUS; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; UBIQUITINATION; VACCINIA VIRUS; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; VIRAL PHENOMENA AND FUNCTIONS; VIRUS; VIRUS DISEASES; VIRUS REPLICATION;

HOST-PATHOGEN INTERACTIONS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; VIRAL PROTEINS; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PHENOMENA; VIRUS REPLICATION; VIRUSES;

EID: 80051931955     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.696     Document Type: Review

References (136)

1. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene 2007; 26: 1306-1316.
2. Vousden KH, Lane DP. p53 in health and disease. Nature Reviews. Molecular Cell Biology 2007; 8: 275-283.
3. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annual Review of Biochemistry 2008; 77: 557-582.
4. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
5. Lu X. Tied up in loops: positive and negative autoregulation of p53. Cold Spring Harbor Perspectives in Biology 2010; 2: a000984.
6. Schwartz D, Rotter V. p53-dependent cell cycle control: response to genotoxic stress. Seminars in Cancer Biology 1998; 8: 325-336.
7. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death and Differentiation 2006; 13: 994-1002.
8. Crighton D, Wilkinson S, O'Prey J, Syed N, Smith P, Harrison PR, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 2006; 126: 121-134.
9. Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445: 656-660.
10. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20: 1803-1815.
11. Oren M. Decision making by p53: life, death and cancer. Cell Death and Differentiation 2003; 10: 431-442.
12. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death and Differentiation 2006; 13: 951-961.
13. Kaustov L, Yi GS, Ayed A, Bochkareva E, Bochkarev A, Arrowsmith CH. p53 transcriptional activation domain: a molecular chameleon? Cell Cycle 2006; 5: 489-494.
14. Feng Z, Hu W, Rajagopal G, Levine AJ. The tumor suppressor p53: cancer and aging. Cell Cycle 2008; 7: 842-847.
15. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nature Reviews. Cancer 2009; 9: 714-723.
16. Halazonetis TD. Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer. DNA Repair (Amst) 2004; 3: 1057-1062.
17. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 2007; 6: 1006-1010.
18. Meek DW, Anderson CW. Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harbor Perspectives in Biology 2009; 1: a000950.
19. Teufel DP, Bycroft M, Fersht AR. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 2009; 28: 2112-2118.
20. Lee CW, Ferreon JC, Ferreon AC, Arai M, Wright PE. Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 19290-19295.
21. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes & Development 1998; 12: 2831-2841.
22. Perry ME. The regulation of the p53-mediated stress response by MDM2 and MDM4. Cold Spring Harbor Perspectives in Biology 2010; 2: a000968.
23. Iwakuma T, Lozano G. MDM2, an introduction. Molecular Cancer Research 2003; 1: 993-1000.
24. Moll UM, Petrenko O. The MDM2-p53 interaction. Molecular Cancer Research 2003; 1: 1001-1008.
25. Brooks CL, Gu W. p53 ubiquitination: Mdm2 and beyond. Molecular Cell 2006; 21: 307-315.
26. Alarcon-Vargas D, Ronai Z. p53-Mdm2--the affair that never ends. Carcinogenesis 2002; 23: 541-547.
27. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-953.
28. Meek DW, Knippschild U. Posttranslational modification of MDM2. Molecular Cancer Research 2003; 1: 1017-1026.
29. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 11598-11603.
30. Blattner C, Hay T, Meek DW, Lane DP. Hypophosphorylation of Mdm2 augments p53 stability. Molecular and Cellular Biology 2002; 22: 6170-6182.
31. Khosravi R, Maya R, Gottlieb T, Oren M, Shiloh Y, Shkedy D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proceedings of the National Academy of Sciences of the United States of America 1999; 96: 14973-14977.
32. Goldberg Z, Vogt Sionov R, Berger M, Zwang Y, Perets R, Van Etten RA, et al. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. The EMBO Journal 2002; 21: 3715-3727.
33. Reich NC, Levine AJ. Specific interaction of the SV40 T antigen-cellular p53 protein complex with SV40 DNA. Virology 1982; 117: 286-290.
34. Jiang D, Srinivasan A, Lozano G, Robbins PD. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 1993; 8: 2805-2812.
35. Lilyestrom W, Klein MG, Zhang R, Joachimiak A, Chen XS. Crystal structure of SV40 large T-antigen bound to p53: interplay between a viral oncoprotein and a cellular tumor suppressor. Genes & Development 2006; 20: 2373-2382.
36. Staib C, Pesch J, Gerwig R, Gerber JK, Brehm U, Stangl A, et al. p53 inhibits JC virus DNA replication in vivo and interacts with JC virus large T-antigen. Virology 1996; 219: 237-246.
37. Coelho TR, Almeida L, Lazo PA. JC virus in the pathogenesis of colorectal cancer, an etiological agent or another component in a multistep process? Virology Journal 2010; 7: 42.
38. Bhatia K, Goedert JJ, Modali R, Preiss L, Ayers LW. Merkel cell carcinoma subgroups by Merkel cell polyomavirus DNA relative abundance and oncogene expression. International Journal of Cancer 2010; 126: 2240-2246.
39. Steegenga WT, Riteco N, Jochemsen AG, Fallaux FJ, Bos JL. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 1998; 16: 349-357.
40. Wienzek S, Roth J, Dobbelstein M. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53. Journal of Virology 2000; 74: 193-202.
41. Liu Y, Colosimo AL, Yang XJ, Liao D. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Molecular and Cellular Biology 2000; 20: 5540-5553.
42. Han JP, Sabbatini P, Perez D, Rao L, Modha D, White E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53 inducible and death promoting Bax protein. Genes & Development. 1996; 10: 461-477.
43. Debbas M, White E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Development 1993; 7: 546-554.
44. Soria C, Estermann FE, Espantman KC, O'Shea CC. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 2010; 466: 1076-1081.
45. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Natural Medicines 1998; 4: 1068-1072.
46. Yi F, Saha A, Murakami M, Kumar P, Knight JS, Cai Q, et al. Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 2009; 388: 236-247.
47. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, Robertson ES. Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. Journal of Virology 2009; 83: 4652-4669.
48. Zhang Q, Gutsch D, Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Molecular and Cellular Biology 1994; 14: 1929-1938.
49. Mauser A, Saito S, Appella E, Anderson CW, Seaman WT, Kenney S. The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. Journal of Virology 2002; 76: 12503-12512.
50. Takemoto M, Koike M, Mori Y, Yonemoto S, Sasamoto Y, Kondo K, et al. Human herpesvirus 6 open reading frame U14 protein and cellular p53 interact with each other and are contained in the virion. Journal of Virology 2005; 79: 13037-13046.
51. Lacroix A, Collot-Teixeira S, Mardivirin L, Jaccard A, Petit B, Piguet C, et al. Involvement of human herpesvirus-6 variant B in classic Hodgkin's lymphoma via DR7 oncoprotein. Clinical Cancer Research 2010; 16: 4711-4721.
52. MacLaine NJ, Oster B, Bundgaard B, Fraser JA, Buckner C, Lazo PA, et al. A central role for CK1 in catalyzing phosphorylation of the p53 transactivation domain at serine 20 after HHV-6B viral infection. The Journal of Biological Chemistry 2008; 283: 28563-28573.
53. Oster B, Kofod-Olsen E, Bundgaard B, Hollsberg P. Restriction of human herpesvirus 6B replication by p53. The Journal of General Virology 2008; 89: 1106-1113.
54. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, et al. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. The New England Journal of Medicine 1996; 335: 233-241.
55. Friborg J, Jr., Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-894.
56. Park J, Seo T, Hwang S, Lee D, Gwack Y, Choe J. The K-bZIP protein from Kaposi's sarcoma-associated herpesvirus interacts with p53 and represses its transcriptional activity. Journal of Virology 2000; 74: 11977-11982.
57. Suzuki T, Isobe T, Kitagawa M, Ueda K. Kaposi's sarcoma-associated herpesvirus-encoded LANA positively affects on ubiquitylation of p53. Biochemical and Biophysical Research Communications 2010; 403: 194-197.
58. Shin YC, Nakamura H, Liang X, Feng P, Chang H, Kowalik TF, et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. Journal of Virology 2006; 80: 2257-2266.
59. Lee SG, Rho HM. Transcriptional repression of the human p53 gene by hepatitis B viral X protein. Oncogene 2000; 19: 468-471.
60. Takada S, Kaneniwa N, Tsuchida N, Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 1997; 15: 1895-1901.
61. Doitsh G, Shaul Y. HBV transcription repression in response to genotoxic stress is p53- dependent and abrogated by pX. Oncogene 1999; 18: 7506-7513.
62. Wang JH, Yun C, Kim S, Chae S, Lee YI, Kim WH, et al. Reactivation of p53 in cells expressing hepatitis B virus X-protein involves p53 phosphorylation and a reduction of Hdm2. Cancer Science 2008; 99: 888-893.
63. Iyer S, Groopman JD. Interaction of mutant hepatitis B X protein with p53 tumor suppressor protein affects both transcription and cell survival. Molecular Carcinogenesis. 2011.
64. Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002; 21: 4801-4811.
65. Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takigawa Y, Ikeda M, Kato N, et al. NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. The Journal of General Virology 2006; 87: 1703-1713.
66. Ariumi Y, Kaida A, Hatanaka M, Shimotohno K. Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain. Biochemical and Biophysical Research Communications 2001; 287: 556-561.
67. Gualberto A, Baldwin AS, Jr. p53 and Sp1 interact and cooperate in the tumor necrosis factor-induced transcriptional activation of the HIV-1 long terminal repeat. The Journal of Biological Chemistry 1995; 270: 19680-19683.
68. Sawaya BE, Khalili K, Mercer WE, Denisova L, Amini S. Cooperative actions of HIV-1 Vpr and p53 modulate viral gene transcription. The Journal of Biological Chemistry 1998; 273: 20052-20057.
69. Wang X, Shen Y, Qiu Y, Shi Z, Shao D, Chen P, et al. The non-structural (NS1) protein of influenza A virus associates with p53 and inhibits p53-mediated transcriptional activity and apoptosis. Biochemical and Biophysical Research Communications 2010; 395: 141-145.
70. Li W, Wang G, Zhang H, Xin G, Zhang D, Zeng J, et al. Effects of NS1 variants of H5N1 influenza virus on interferon induction, TNFalpha response and p53 activity. Cellular & Molecular Immunology 2010; 7: 235-242.
71. Shen Y, Wang X, Guo L, Qiu Y, Li X, Yu H, et al. Influenza A virus induces p53 accumulation in a biphasic pattern. Biochemical and Biophysical Research Communications 2009; 382: 331-335.
72. Santos CR, Vega FM, Blanco S, Barcia R, Lazo PA. The vaccinia virus B1R kinase induces p53 downregulation by an Mdm2-dependent mechanism. Virology 2004; 328: 254-265.
73. Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock AN, et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 20523-20528.
74. Boutell C, Everett RD. Herpes simplex virus type 1 infection induces the stabilization of p53 in a USP7- and ATM-independent manner. Journal of Virology 2004; 78: 8068-8077.
75. Castillo JP, Frame FM, Rogoff HA, Pickering MT, Yurochko AD, Kowalik TF. Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrest response. Journal of Virology 2005; 79: 11467-11475.
76. Banham AH, Smith GL. Vaccinia virus gene B1R encodes a 34-kDa serine/threonine protein kinase that localizes in cytoplasmic factories and is packaged into virions. Virology 1992; 191: 803-812.
77. Rempel RE, Anderson MK, Evans E, Traktman P. Temperature-sensitive vaccinia virus mutants identify a gene with an essential role in viral replication. Journal of Virology 1990; 64: 574-583.
78. Wali A, Strayer DS. Infection with vaccinia virus alters regulation of cell cycle progression. DNA and Cell Biology 1999; 18: 837-843.
79. Santos CR, Blanco S, Sevilla A, Lazo PA. Vaccinia virus B1R kinase interacts with JIP1 and modulates c-Jun-dependent signaling. Journal of Virology 2006; 80: 7667-7675.
80. Lopez-Borges S, Lazo PA. The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. Oncogene 2000; 19: 3656-3664.
81. Vega FM, Sevilla A, Lazo PA. p53 stabilization and accumulation induced by human vaccinia-related kinase 1. Molecular and Cellular Biology 2004; 24: 10366-10380.
82. Valbuena A, Castro-Obregon S, Lazo PA. Downregulation of VRK1 by p53 in Response to DNA damage is mediated by the autophagic pathway. PLoS ONE 2011; 6: e17320.
83. Sevilla A, Santos CR, Barcia R, Vega FM, Lazo PA. c-Jun phosphorylation by the human vaccinia-related kinase 1 (VRK1) and its cooperation with the N-terminal kinase of c-Jun (JNK). Oncogene 2004; 23: 8950-8958.
84. Weston CR, Davis RJ. The JNK signal transduction pathway. Current Opinion in Cell Biology 2007; 19: 142-149.
85. Sato Y, Shirata N, Murata T, Nakasu S, Kudoh A, Iwahori S, et al. Transient increases in p53-responsible gene expression at early stages of Epstein-Barr virus productive replication. Cell Cycle 2010; 9: 807-814.
86. Sato Y, Kamura T, Shirata N, Murata T, Kudoh A, Iwahori S, et al. Degradation of phosphorylated p53 by viral protein-ECS E3 ligase complex. PLoS Pathogens 2009; 5: e1000530.
87. Sato Y, Shirata N, Kudoh A, Iwahori S, Nakayama S, Murata T, et al. Expression of Epstein-Barr virus BZLF1 immediate-early protein induces p53 degradation independent of MDM2, leading to repression of p53-mediated transcription. Virology 2009; 388: 204-211.
88. Li L, Guo L, Tao Y, Zhou S, Wang Z, Luo W, et al. Latent membrane protein 1 of Epstein-Barr virus regulates p53 phosphorylation through MAP kinases. Cancer Letters 2007; 255: 219-231.
89. Oster B, Bundgaard B, Hupp TR, Hollsberg P. Human herpesvirus 6B induces phosphorylation of p53 in its regulatory domain by a CK2- and p38-independent pathway. The Journal of General Virology 2008; 89: 87-96.
90. Nishimura T, Kohara M, Izumi K, Kasama Y, Hirata Y, Huang Y, et al. Hepatitis C virus impairs p53 via persistent overexpression of 3beta-hydroxysterol Delta24-reductase. The Journal of Biological Chemistry 2009; 284: 36442-36452.
91. Muench P, Probst S, Schuetz J, Leiprecht N, Busch M, Wesselborg S, et al. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Research 2010; 70: 6913-6924.
92. Hsu CH, Chang MD, Tai KY, Yang YT, Wang PS, Chen CJ, et al. HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. The EMBO Journal 2004; 23: 2269-2280.
93. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136.
94. Thomas M, Matlashewski G, Pim D, Banks L. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV18 E6 through ubiquitin mediated degradation. Oncogene 1996; 13: 265-273.
95. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999; 18: 7690-7700.
96. Lepik D, Ustav M. Cell-specific modulation of papovavirus replication by tumor suppressor protein p53. Journal of Virology 2000; 74: 4688-4697.
97. Brown C, Kowalczyk AM, Taylor ER, Morgan IM, Gaston K. P53 represses human papillomavirus type 16 DNA replication via the viral E2 protein. Virology Journal 2008; 5: 5.
98. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-937.
99. White AE, Livanos EM, Tlsty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes & Development 1994; 8: 666-677.
100. Thomas JT, Laimins LA. Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. Journal of Virology 1998; 72: 1131-1137.
101. Guo C, Liu K, Zheng Y, Luo H, Chen H, Huang L. Apoptosis induced by an antagonist peptide against HPV16 E7 in vitro and in vivo via restoration of p53. Apoptosis. 2011.
102. Boutell C, Everett RD. The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and ubiquitinates p53. The Journal of Biological Chemistry 2003; 278: 36596-36602.
103. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES. EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathogens 2006; 2: e116.
104. Lee HR, Toth Z, Shin YC, Lee JS, Chang H, Gu W, et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. Journal of Virology 2009; 83: 6739-6747.
105. Zhang Z, Evers DL, McCarville JF, Dantonel JC, Huong SM, Huang ES. Evidence that the human cytomegalovirus IE2-86 protein binds mdm2 and facilitates mdm2 degradation. Journal of Virology 2006; 80: 3833-3843.
106. Chen Z, Knutson E, Wang S, Martinez LA, Albrecht T. Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. The Journal of Biological Chemistry 2007; 282: 29284-29295.
107. Casavant NC, Luo MH, Rosenke K, Winegardner T, Zurawska A, Fortunato EA. Potential role for p53 in the permissive life cycle of human cytomegalovirus. Journal of Virology 2006; 80: 8390-8401.
108. Wang J, Belcher JD, Marker PH, Wilcken DE, Vercellotti GM, Wang XL. Cytomegalovirus inhibits p53 nuclear localization signal function. Journal of Molecular Medicine 2001; 78: 642-647.
109. Utama B, Shen YH, Mitchell BM, Makagiansar IT, Gan Y, Muthuswamy R, et al. Mechanisms for human cytomegalovirus-induced cytoplasmic p53 sequestration in endothelial cells. Journal of Cell Science 2006; 119: 2457-2467.
110. Noris E, Zannetti C, Demurtas A, Sinclair J, De Andrea M, Gariglio M, et al. Cell cycle arrest by human cytomegalovirus 86-kDa IE2 protein resembles premature senescence. Journal of Virology 2002; 76: 12135-12148.
111. Song YJ, Stinski MF. Inhibition of cell division by the human cytomegalovirus IE86 protein: role of the p53 pathway or cyclin-dependent kinase 1/cyclin B1. Journal of Virology 2005; 79: 2597-2603.
112. Technau-Ihling K, Ihling C, Kromeier J, Brandner G. Influenza a virus infection of mice induces nuclear accumulation of the tumorsuppressor protein p53 in the lung. Archives of Virology 2001; 146: 1655-1666.
113. Turpin E, Luke K, Jones J, Tumpey T, Konan K, Schultz-Cherry S. Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication. Journal of Virology 2005; 79: 8802-8811.
114. Zhirnov OP, Klenk HD. Control of apoptosis in influenza virus-infected cells by up-regulation of Akt and p53 signaling. Apoptosis 2007; 12: 1419-1432.
115. Sun M, Fuentes SM, Timani K, Sun D, Murphy C, Lin Y, et al. Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses. Journal of Virology 2008; 82: 105-114.
116. Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 2002; 21: 1299-1303.
117. Groskreutz DJ, Monick MM, Yarovinsky TO, Powers LS, Quelle DE, Varga SM, et al. Respiratory syncytial virus decreases p53 protein to prolong survival of airway epithelial cells. Journal of Immunology 2007; 179: 2741-2747.
118. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006; 344: 119-130.
119. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516-523.
120. Marques JT, Rebouillat D, Ramana CV, Murakami J, Hill JE, Gudkov A, et al. Down-regulation of p53 by double-stranded RNA modulates the antiviral response. Journal of Virology 2005; 79: 11105-11114.
121. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Criado LM, Klatt P, Flores JM, et al. 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. The EMBO Journal 2002; 21: 6225-6235.
122. Munoz-Fontela C, Garcia MA, Garcia-Cao I, Collado M, Arroyo J, Esteban M, et al. Resistance to viral infection of super p53 mice. Oncogene 2005; 24: 3059-3062.
123. Wiman KG. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Advances in Cancer Research 2007; 97: 321-338.
124. Joerger AC, Fersht AR. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harbor Perspectives in Biology 2010; 2: a000919.
125. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harbor Perspectives in Biology 2010:a001222.
126. Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 2010; 468: 572-575.
127. Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010; 468: 567-571.
128. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 10360-10365.
129. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. British Journal of Cancer 2004; 91: 1415-1419.
130. Sarek G, Kurki S, Enback J, Iotzova G, Haas J, Laakkonen P, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. The Journal of Clinical Investigation 2007; 117: 1019-1028.
131. Sarek G, Ojala PM. p53 reactivation kills KSHV lymphomas efficiently in vitro and in vivo: new hope for treating aggressive viral lymphomas. Cell Cycle 2007; 6: 2205-2209.
132. Petre CE, Sin SH, Dittmer DP. Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy. Journal of Virology 2007; 81: 1912-1922.
133. Renouf B, Hollville E, Pujals A, Tetaud C, Garibal J, Wiels J. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Leukemia 2009; 23: 1557-1563.
134. Forte E, Luftig MA. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. Journal of Virology 2009; 83: 2491-2499.
135. Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, et al. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 2010; 18: 411-422.
136. McNamara CR, Degterev A. Small-molecule inhibitors of the PI3K signaling network. Future Medicinal Chemistry 2011; 3: 549-565.